CD274 and hereditary clear cell renal cell carcinoma: In renal cell carcinoma, several phase 3 clinical trials showed anti-VEGF or anti-VEGF receptor plus PD-1 or PD-L1 inhibition showed prolonged progression-free survival with favorable safety profile [46,47].